Gilead Sciences to Acquire Ouro Medicines, Expanding Autoimmune Therapy Portfolio with OM336 Bispecific T Cell Engager

Gilead Sciences to acquire Ouro Medicines for $1.675 bln, expanding its autoimmune therapy portfolio. The acquisition adds OM336, a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio. Gilead will pay up to $500 mln in contingent milestone payments. The deal is subject to customary closing conditions and remains under review.